Newsroom

Sorted by: Latest

-

Janus International Group to Report Fourth Quarter and Full Year 2025 Results on March 4, 2026

TEMPLE, Ga.--(BUSINESS WIRE)--Janus International Group, Inc. (NYSE: JBI) (“Janus” or the “Company”), a leading global provider of building product solutions and cutting-edge access control technologies for the self-storage and other commercial and industrial sectors, announced today that the Company will release its fourth quarter and full year 2025 financial results after the market closes on Wednesday, March 4, 2026. A webcast and conference call will be held the following day, on Thursday,...
-

USA Compression Partners Reports Fourth-Quarter 2025 Results and Provides 2026 Outlook; Achieves Record Results

DALLAS--(BUSINESS WIRE)--USA Compression Partners, LP (NYSE: USAC) (“USA Compression” or the “Partnership”) announced today its financial and operating results for fourth-quarter 2025. Financial Highlights Record total revenues of $252.5 million for fourth-quarter 2025, compared to $245.9 million for fourth-quarter 2024. Net income was $27.8 million for fourth-quarter 2025, compared to $25.4 million for fourth-quarter 2024. Net cash provided by operating activities was $139.5 million for fourth...
-

UK Debt Management Office UK Regulatory Announcement: Issue of Debt

LONDON--(BUSINESS WIRE)--      DMO-TAS041/3630/002         The Minster Building21 Mincing LaneLondonEC3R 7AG T 020 7862 6500F 020 7862 6509www.dmo.gov.uk           A024\26 17 February 2026   PRESS NOTICE   RESULT OF THE SALE BY TENDER OF UP TO £750 MILLION OF 4¼% TREASURY STOCK 2032The United Kingdom Debt Management Office ("DMO") announces that the tender of up to £750 million of 4¼% Treasury Stock 2032 (ISIN Code: GB0004893086) has been allocated as follows:(Note: all prices in this notice ar...
-

Fluor Receives $1.35 Billion for 71 Million NuScale Shares; Launches Trading Program for Remaining 40 Million Shares

IRVING, Texas--(BUSINESS WIRE)--FLUOR RECEIVES $1.35 BILLION FOR 71 MILLION NUSCALE SHARES; LAUNCHES TRADING PROGRAM FOR REMAINING 40 MILLION SHARES...
-

Rasan Reports Record FY 2025 Results with 82% Revenue Growth to SAR 653 Million and Adjusted Net Income Nearly Tripling

RIYADH, Saudi Arabia--(BUSINESS WIRE)--Rasan Reports Record FY 2025 Results with 82% Revenue Growth to SAR 653 Million and Adjusted Net Income Nearly Tripling...
-

Fluor Reports Fourth Quarter and Full Year 2025 Results

IRVING, Texas--(BUSINESS WIRE)--Fluor Corporation (NYSE: FLR) announced financial results for its year ended December 31, 2025. “Our growing confidence in capturing significant EPC awards in 2026 and into 2027 is supported by an improving capital spending environment and increasing client commitments,” said Jim Breuer, chief executive officer of Fluor. “Furthermore, I am pleased that the monetization of our NuScale investment is progressing well and that we are returning significant value to ou...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Innovative Transaction & Process UCITS ETF 16.02.2026 LEGR LN IE00BF5DXP42 1,025,002.00 USD 51,243,369.94 49.993  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust NASDAQ Clean Edge Green Energy UCITS ETF 16.02.2026 QCLN.LN IE00BDBRT036 625,002.00 USD 12,159,025.94 19.454  ...
-

DNOW Announces Fourth Quarter and Full-Year 2025 Earnings Conference Call

HOUSTON--(BUSINESS WIRE)--DNOW Announces Fourth Quarter and Full-Year 2025 Earnings Conference Call...
-

Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The BRAFTOVI regimen demonstrated a statistically sig...